Primary binding
|
Heparin-like molecules |
HCV-HSPG interaction |
[6, 7, 8, 53] |
Epigallocatechin gallate |
HCV-HSPG interaction |
[54–56] |
Tannic acid |
Docking of HCV at cell surface |
[57] |
Gallic acid |
Docking of HCV at cell surface |
[58] |
Delphinidin |
Docking of HCV at cell surface |
[59] |
Specific binding
|
281816 |
HCV E2-CD81 interaction |
[60] |
Oleanane-type triterpenes |
HCV E2-CD81 interaction |
[61] |
Saikosaponin b2 |
HCV E2-CD81 interaction |
[62] |
Anti-CD81 antibody |
HCV E2-CD81 interaction |
[63] |
Anti-SRBI antibody |
HCV-SRBI interaction |
[64, 65] |
Anti-ApoE antibody |
HCV-associated ApoE-HSPG interaction |
[5] |
Neutralizing antibodies |
HCV E1/E2 |
[66–68] |
Polyclonal anti-HCV IgG
|
HCV E1/E2 |
[69, 70] |
ApoE-derived peptide |
HCV-associated ApoE-HSPG interaction |
[71] |
Post-binding
|
Anti-CLDN1 antibodies |
CD81-CLDN1 coreceptor complex |
[48, 72–75] |
CLDN1-derived peptide |
CD81-CLDN1 coreceptor complex |
[76] |
Erlotinib
|
CD81-CLDN1 coreceptor complex; signaling |
[23] |
ITX5061
|
SRBI lipid transfer activity |
[77] |
Internalization
|
Arbidol |
HCV endosomal trafficking |
[78] |
Silibinin |
HCV endosomal trafficking |
[79] |
Fusion
|
Flunarizine |
HCV genotype 2 fusion (E1 and/or E2) |
[38] |
Ferroquine |
HCV fusion (E1) |
[81] |
RAFIs |
HCV envelope curvature |
[85, 86] |
Phenothiazines |
HCV envelope fluidity |
[87] |
Benzhydrylpiperazines |
HCV envelope fluidity |
[88] |
Curcumin |
HCV envelope fluidity |
[89] |
Polyunsaturated liposomes |
Cellular membrane (cholesterol depletion) |
[90] |
Statins |
Cellular membrane (cholesterol depletion) |
[91] |
Ezetimibe
|
Cellular membrane (cholesterol depletion) |
[30] |
Photosensitizers (LJ001) |
Lipid oxidation (viral envelope) |
92, 93] |